These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Conjugation of 5-fluoro-2'-deoxyuridine with lactosaminated poly-l-lysine to reduce extrahepatic toxicity in the treatment of hepatocarcinomas.
    Author: Di Stefano G, Busi C, Derenzini M, Trerè D, Fiume L.
    Journal: Ital J Gastroenterol Hepatol; 1998 Apr; 30(2):173-7. PubMed ID: 9675653.
    Abstract:
    BACKGROUND: The hepatocyte receptor for asialoglycoproteins, which binds and internalizes galactosyl-terminating peptides, was found to be expressed also on the cells of well differentiated hepatocarcinomas. AIMS: We explored the possibility of obtaining a delivery of antiblastic drugs to hepatocarcinoma cells through this receptor. METHODS: We conjugated 5-fluoro-2'-deoxyuridine (FUDR) with lactosaminated poly-L-lysine. 5-fluoro-2'-deoxyuridine is an active drug in the treatment of solid tumours, but with toxic effects on intestine and bone marrow. Poly-L-lysine is an galactosyl-terminating carrier which enables preparation of conjugates with very high drug load. We studied the pharmacological activity of poly-L-lysine-5-fluoro-2'-deoxyuridine conjugate on in vitro proliferation of Hep G2 cells, a human hepatocarcinoma cell line. Moreover, we compared the levels of radioactivity in liver, intestine and heart of mice injected with free or conjugated [3H]5-fluoro-2'-deoxyuridine. RESULTS: We found that poly-L-lysine-5-fluoro-2'-deoxyuridine enters into Hep G2 cells through the asialoglycoprotein receptor and, after intracellular penetration, releases the drug in a pharmacologically active form. Administered to mice, the conjugate leads to enhanced accumulation of the drug in liver versus the intestine and the heart. CONCLUSIONS: These data support conjugation with poly-L-lysine as a way to obtain drug targeting to those hepatocellular carcinomas which maintain the asialoglycoprotein receptor.
    [Abstract] [Full Text] [Related] [New Search]